問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Principal Investigator

蘇五洲

List

133Cases

2006-10-01 - 2008-10-01

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2020-03-01 - 2023-12-31

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2011-10-01 - 2013-09-30

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2016-01-01 - 2019-08-31

Phase III

An international, randomised, multi-centre, active controlled, open-label Phase III study evaluating the efficacy of in patients with T790M-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed on one epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment

  • Condition/Disease

    Non-Small Cell Lung Cancer (NSCLC)

  • Test Drug

    AZD9291

Participate Sites
9Sites

Terminated8Sites

楊政達
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

鍾飲文
Kaohsiung Municipal Gangshan Hospital

未分科

2011-03-01 - 2015-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2007-11-01 - 2011-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2016-02-26 - 2018-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2021-09-01 - 2025-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2015-09-01 - 2018-12-24

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2012-09-01 - 2018-01-04

Phase III

Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination with Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen

  • Condition/Disease

    Metastatic Castration Resistant Prostate Cancer

  • Test Drug

    XRP6258

Participate Sites
3Sites

Terminated2Sites

Study ended1Sites

1 2 3 4 5 6 14
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB